3-Dimensional Strain Analysis of Hypertrophic Cardiomyopathy: Insights From the NHLBI International HCM Registry.
cardiac magnetic resonance
hypertrophic cardiomyopathy
late gadolinium enhancement
left ventricular hypertrophy
sarcomere
strain
Journal
JACC. Cardiovascular imaging
ISSN: 1876-7591
Titre abrégé: JACC Cardiovasc Imaging
Pays: United States
ID NLM: 101467978
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
22
02
2022
revised:
04
10
2022
accepted:
13
10
2022
medline:
7
4
2023
pubmed:
18
1
2023
entrez:
17
1
2023
Statut:
ppublish
Résumé
Abnormal global longitudinal strain (GLS) has been independently associated with adverse cardiac outcomes in both obstructive and nonobstructive hypertrophic cardiomyopathy. The goal of this study was to understand predictors of abnormal GLS from baseline data from the National Heart, Lung, and Blood Institute (NHLBI) Hypertrophic Cardiomyopathy Registry (HCMR). The study evaluated comprehensive 3-dimensional left ventricular myocardial strain from cine cardiac magnetic resonance in 2,311 patients from HCMR using in-house validated feature-tracking software. These data were correlated with other imaging markers, serum biomarkers, and demographic variables. Abnormal median GLS (> -11.0%) was associated with higher left ventricular (LV) mass index (93.8 ± 29.2 g/m Abnormal strain in hypertrophic cardiomyopathy is associated with other imaging and serum biomarkers of increased risk. Further follow-up of the HCMR cohort is needed to understand the independent relationship between LV strain and adverse cardiac outcomes in hypertrophic cardiomyopathy.
Sections du résumé
BACKGROUND
Abnormal global longitudinal strain (GLS) has been independently associated with adverse cardiac outcomes in both obstructive and nonobstructive hypertrophic cardiomyopathy.
OBJECTIVES
The goal of this study was to understand predictors of abnormal GLS from baseline data from the National Heart, Lung, and Blood Institute (NHLBI) Hypertrophic Cardiomyopathy Registry (HCMR).
METHODS
The study evaluated comprehensive 3-dimensional left ventricular myocardial strain from cine cardiac magnetic resonance in 2,311 patients from HCMR using in-house validated feature-tracking software. These data were correlated with other imaging markers, serum biomarkers, and demographic variables.
RESULTS
Abnormal median GLS (> -11.0%) was associated with higher left ventricular (LV) mass index (93.8 ± 29.2 g/m
CONCLUSIONS
Abnormal strain in hypertrophic cardiomyopathy is associated with other imaging and serum biomarkers of increased risk. Further follow-up of the HCMR cohort is needed to understand the independent relationship between LV strain and adverse cardiac outcomes in hypertrophic cardiomyopathy.
Identifiants
pubmed: 36648040
pii: S1936-878X(22)00610-6
doi: 10.1016/j.jcmg.2022.10.005
pii:
doi:
Substances chimiques
Contrast Media
0
Gadolinium
AU0V1LM3JT
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
478-491Subventions
Organisme : British Heart Foundation
ID : PG/15/71/31731
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : U01 HL117006
Pays : United States
Organisme : Department of Health
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Funding Support and Author Disclosures HCMR was supported by the National Institutes of Health, the National Heart, Lung, and Blood Institute (U01HL117006-01A1), and the NIHR Oxford Biomedical Research Centre. Dr Kramer has received research grants from and been consultant for MyoKardia and Cytokinetics. Dr Antiochos has received research funding from the Swiss National Science Foundation (grant P2LAP3_184037), the Novartis Foundation for Medical-Biological Research, the Bangerter-Rhyner Foundation, and the SICPA Foundation. Dr Kwong has received research support from Siemens Healthineers, Bayer AG, and MyoKardia. Dr Maron has received consulting and research support from iRhythm; and has been a consultant for Celltrion and Cytokinetics. Dr Friedrich has been a board member, shareholder, and consultant of Circle Cardiovascular Imaging Inc. Dr Schulz-Menger has been a consultant for Bayer; has received research grants from Bayer, Siemens Healthineers, and Circle Cardiovascular Imaging. Dr Piechnik holds U.S. patent 9,285,446 B2 (“Systems and methods for shortened look locker inversion recovery [Sh-MOLLI] cardiac gated mapping of T1”). Dr White holds shares in Cohesic and has received a research grant from Siemens Healthineers. Dr Neubauer has received research grants from Boehringer Ingelheim and Cytokinetics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.